Compositions comprising axitinib and methods of treating ocular disorders
AssigneeClearside Biomedical, Inc.
InventorsViral KANSARA, Thomas Ciulla, Colette Hall, Barry Kapik
Life of this patent
Estimating the term…
Abstract
This disclosure is generally related to ophthalmic therapies, and more particularly to methods and devices that allow for infusion of a fluid drug formulation into posterior ocular tissues for targeted, localized treatment, for example, for the treatment of wet AMD in human patients. The drug formulation may be injected into the suprachoroidal space (SCS) or subretinal space of an eye. The drug formulation may include a tyrosine kinase inhibitor, such as axitinib.
Claims32
A method of treating neovascular age-related macular degeneration (nAMD), choroidal neovascularization (CNV), or nAMD associated with CNV comprising,
- non-surgically administering an effective amount of a formulation comprising axitinib to the suprachoroidal space (SCS) of the eye of a human subject in need thereof,
- wherein the effective amount of axitinib in the formulation is about 0.5 mg to about 1.0 mg.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating neovascular age-related macular degeneration (nAMD), choroidal neovascularization (CNV), or nAMD associated with CNV comprising, non-surgically administering an effective amount of a formulation comprising axitinib to the suprachoroidal space (SCS) of the eye of a human subject in need thereof, wherein the effective amount of axitinib in the formulation is about 0.5 mg to about 1.0 mg, and wherein the human subject has been previously administered with a VEGF antagonist.
Dependencies are inferred from the claim text.